कंपनी का अवलोकन
Alumis Inc. operates as a clinical stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic agents specifically targeting autoimmune disorders. The company functions within the healthcare sector and the biotechnology industry, sectors characterized by high research and development expenditures aimed at creating novel medicines for complex medical conditions. Alumis maintains a market capitalization of $2.92B while reporting a trailing twelve-month revenue of $24.05M and employing 221 individuals across its operations. These valuation and revenue metrics indicate that the market assigns a significant premium to the company's potential pipeline, particularly regarding its lead candidate envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor designed for the treatment of plaque psoriasis and systemic lupus erythematosus, despite the current lack of commercial revenue generation from these products.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $24.05M, yet it recorded a net income of $-243,324,992 and an EBITDA of $-438,408,000, revealing a substantial gap between top-line sales and bottom-line profitability. This discrepancy highlights an aggressive cost structure where operating expenses, likely driven by clinical trial costs and research activities, significantly exceed current revenue streams, resulting in a profit margin of 0.0%. The firm generated free cash flow of $-202,334,000, which indicates a heavy cash burn rate typical of clinical stage biotechnology companies that are not yet commercially profitable. However, the balance sheet holds $308.50M in cash against $36.91M in debt, providing a substantial liquidity buffer to fund ongoing operations without immediate refinancing needs. The debt-to-equity ratio stands at 12.25, suggesting a highly leveraged capital structure relative to equity, though the absolute debt load is manageable given the cash reserves. The current ratio is 4.34, indicating a strong position in meeting short-term obligations with current assets relative to current liabilities. Furthermore, the return on equity is -86.7% and the return on assets is -73.4%, metrics that reflect the dilutive effect of losses on shareholder value and asset base efficiency during the pre-commercialization phase.
मूल्यांकन आकलन
Alumis Inc. does not have a trailing P/E ratio, while the forward P/E is listed as -7.09, a valuation metric that implies negative earnings expectations and the absence of a traditional multiple based on current profitability. The price-to-book ratio is 7.97, indicating that the market values the company at nearly eight times its book value, a premium often seen in biotech firms betting on future asset appreciation or pipeline value rather than current tangible assets. The price-to-sales ratio is 121.33, and the EV/EBITDA is -6.04, suggesting that valuation is heavily dependent on future potential rather than current cash flows or earnings power. The stock has a 52-week high of $30.60 and a 52-week low of $2.76, meaning the share price is currently trading at a level that reflects significant volatility within this wide range, though the exact current price percentage relative to the high cannot be calculated without the real-time price data provided in the prompt. The beta value is N/A, which implies that historical volatility data may be insufficient to calculate a standard deviation relative to the broader market, or the metric is not reported for this specific entity. These alternative valuation multiples suggest that investors are pricing in the success of the TYK2 inhibitor pipeline rather than current financial performance.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet achieved consistent commercial sales to generate comparable growth rates for analysis. Consequently, the earnings cannot be growing faster or slower than revenue in a traditional sense because the financial results are defined by the progression of clinical development rather than sales expansion. Regarding income, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status indicates that the company retains all earnings, if any, and reinvests capital entirely into research, development, and commercialization efforts rather than paying returns to investors. The overall growth and income profile is characterized by a reliance on future product approvals and commercial launches to transition from a cash-burning clinical stage entity to a profitable commercial biopharmaceutical business, with no current reliance on dividend income for investors.